91085-89-1

Usage

Uses

Used in Organic Synthesis:
1-(3-Bromopropyl)-3-chlorobenzene is used as a key intermediate in organic synthesis for the creation of a variety of complex organic molecules. Its unique structure and reactivity allow for the formation of new chemical bonds and the development of novel compounds with diverse properties.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(3-Bromopropyl)-3-chlorobenzene is utilized as a starting material or building block in the development of new drugs. Its chemical properties make it suitable for the synthesis of drug candidates with potential therapeutic applications.
Used in Industrial Chemical Production:
1-(3-Bromopropyl)-3-chlorobenzene is also employed in the production of various industrial chemicals. Its versatility and reactivity contribute to the manufacturing of a range of chemical products used in different industries.

Upstream product

• 22991-03-3 3-(3-chlorophenyl)propanol 
• 108-37-2 1-bromo-3-chlorobenzene 
• 109-64-8 1,3-dibromo-propane 
• 21640-48-2 3-chlorohydrocinnamic acid 
• 1866-38-2 m-Chlorocinnamic acid 
• 587-04-2 m-Chlorobenzaldehyde 
• 42175-03-1 methyl (E)-3-(3-chlorophenyl)prop-2-enoate 

Downstream Products

• 112442-43-0 13-(3-chloro-phenyl)-tridecanoic acid 
• 103394-97-4 N-[3-(3-chloro-phenyl)-propyl]-aniline 
• 112298-31-4 5-(m-chlorophenyl)-1,1,1-trifluoropentan-2-one 
• 86373-23-1 4-[3-(3-Chloro-phenyl)-propylamino]-benzoic acid ethyl ester 
• 112298-37-0 6-chloro-1-phenyl-1-(trifluoromethyl)-1,2,3,4-tetrahydronaphthalene 
• 112298-19-8 5-(m-chlorophenyl)-2-phenyl-1,1,1-trifluoropentan-2-ol 
• 129255-23-8 1-(3-chlorophenyl)-4-(3-methyl-pyridin-4-yl)butane 
• 129255-20-5 1-(3-chlorophenyl)-4-(3-ethyl-pyridin-4-yl)-butane 
• 1093172-56-5 [5-(2-{4-[3-(3-chlorophenyl)propoxy]-3-trifluoromethylphenyl}ethyl)-2,2-dimethyl-1,3-dioxan-5-yl]carbamic acid t-butyl ester 
• 107821-67-0 12-(3-chloro-phenyl)-dodecylamine 
• 3297-76-5 1-phenyl-1,2,3,4-tetrahydroquinoline 
• 86373-24-2 4-[3-(3-Chloro-phenyl)-propylamino]-benzoic acid 
• 181650-48-6 4-(3-chlorophenyl)-1,-butylamine 
• 22991-04-4 1-Cyan-3-(3-chlor-phenyl)-propan 

Relevant academic research and scientific papers

B(C6F5)3-Catalyzed Diastereoselective Formal (4 + 1)-Cycloaddition of Vinylcyclopropanes and Et2SiH2

A formal (4 + 1)-cycloaddition of vinylcyclopropanes and Et2SiH2 to afford 3,4-disubstituted silolanes is reported. The reaction sequence commences with the known B(C6F5)3-catalyzed alkene hydrosilylation with dihydrosilanes. Cleavage of the remaining Si-H bond in the hydrosilylation product assisted by B(C6F5)3 leads to formation of a cyclopropane-stabilized silylium ion. The activated cyclopropane ring is then opened by the in situ-generated borohydride accompanied by ring closure to the silolane. The diastereoselectivity is rationalized by a mechanistic model.

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity

The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(–)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM3R). Compared to 1 and 5, (R)-(–)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(–)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(–)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.

Picolinic acids as β-exosite inhibitors of botulinum neurotoxin A light chain

In developing small-molecule inhibitors of botulinum neurotoxin serotype A light chain (BoNT/A LC), substituted picolinic acids were identified. Extensive investigation into the SAR of the picolinic acid scaffold revealed 5-(1-butyl-4-chloro-1H-indol-2-yl)picolinic acid (CBIP), which possessed low micromolar activity against BoNT/A. Kinetic and docking studies demonstrated binding of CBIP to the β-exosite: a largely unexplored site on the LC that holds therapeutic relevance for botulism treatment.

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects

The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.

Method for treating glaucoma

Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.

Prevention of loss and restoration of bone mass by certain prostaglandin agonists

Prostaglandin agonists of formula (I), in which, for example, A is a sulphonyl or acyl group, B is N or CH, M contains a ring and K and Q are linking groups, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits useful for the treatment of bone disorders including osteoporosis. STR1